Protein Polymer Technologies Submits 510(k) Application For Expanded Indications Of Its Embolization Products

Protein Polymer Technologies, Inc. (OTC BB: PPTI), a biotechnology device company that is a pioneer in protein design and synthesis, announced that it has filed a 510(k) application with the U.S. Food and Drug Administration (FDA) for clearance to expand the labeled indications of Surgica's embolization products to include treatment of hypervascular tumors including uterine fibroids, liver and renal tumors.

Back to news